CN102058694B - Application of pharmaceutical composition consisting of amino acids and extracts - Google Patents
Application of pharmaceutical composition consisting of amino acids and extracts Download PDFInfo
- Publication number
- CN102058694B CN102058694B CN201010616182A CN201010616182A CN102058694B CN 102058694 B CN102058694 B CN 102058694B CN 201010616182 A CN201010616182 A CN 201010616182A CN 201010616182 A CN201010616182 A CN 201010616182A CN 102058694 B CN102058694 B CN 102058694B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- sheet
- blue
- extracts
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention provides application of a pharmaceutical composition consisting of amino acids and extracts to preparing medicines for reinforcing memory, breeding hair and preventing alopecia, preventing and treating senile dementia, cerebral infarction and dizziness, head swell, headache and dim eyesight caused by long time use of computer or driving. The amino acids are ornithine and citrulline or salts thereof and the natural extracts are Chinese-date, gingkgo and ginseng extracts. The pharmaceutical composition can remarkably improve the content of superoxide dismutase and reduce the content of malondialdehyde in brain tissues of a mouse, reduce the damage of free radicals to the neural system, avoid and improve dementia and remarkably improve memory of animals with dysmnesia. The pharmaceutical composition can further relieve dizziness, head swell, headache and dim eyesight caused by long time use of computer or driving and has the function of breeding hair and preventing alopecia. The pharmaceutical composition can be prepared into granular formulation or oral liquid and is suitable for patients with dementia and cerebral infarction.
Description
Technical field
The present invention relates to a kind of purposes of Pharmaceutical composition; The Pharmaceutical composition that particularly relates to a kind of natural amino acid and natural extract composition is at hypermnesis; Hair-growing and anti-hair loss prevents and treats that alzheimer disease, cerebral infarction and long-time uses that computer or dizziness, head that driving produced rise, the purposes of headache and dim eyesight aspect.
Background technology
Existing patent (03117070.6) and is disclosed a kind of Pharmaceutical composition; Form by natural amino acid and natural extract; Natural amino acid is ornithine and citrulline or its esters; Natural extract is Fructus Jujubae, Semen Ginkgo and Radix Ginseng extract, and wherein natural amino acid and natural extract were with 4: 1 mixed; Main active ornithine and citrulline or its esters mix preferred 1: 1 with 3/1 to 1/3; Main active Fructus Jujubae, Semen Ginkgo and Radix Ginseng extract be with any mixed, preferred 2: 1: 1.
Above-mentioned Pharmaceutical composition has the favourable resultant effect of the following disease of treatment: sexual disorder, sexual impotence, hypoimmunity, confirmed fatigue and hepatic disfunction.Said composition has obvious effect to sexual function improvement, and has no side effect, and is safe, can take for a long time, is the first-selected product that people improve quality of life and health care.
Above-mentioned Pharmaceutical composition has obtained national health food authentication code (2006B0578), and name of product is the blue sheet of supporting of silent board difficult to understand, and health care is for improving anoxia endurance, chemical liver injury being had auxiliary protection function.
Patent 03117070.6 discloses also that said composition adds or do not add medicinal tax agent can be made into tablet, capsule, chewable tablet, instant liquid sheet.Tablet can add sugar-coat.
Summary of the invention
The object of the invention is to provide a kind of Pharmaceutical composition at hypermnesis, and hair-growing and anti-hair loss prevents and treats that alzheimer disease, cerebral infarction and long-time uses that computer or dizziness, head that driving produced rise, the purposes of headache and dim eyesight aspect.
Natural amino acid in the said Pharmaceutical composition is ornithine and citrulline or its esters, and natural extract is Fructus Jujubae, Semen Ginkgo and Radix Ginseng extract; Pharmaceutical composition main active natural amino acid and natural extract mix with 4: 1 weight ratios; Main active ornithine and citrulline or its esters mix with 3: 1 to 1: 3 weight ratios, and weight ratio was mixed in preferred 1: 1; Main active Fructus Jujubae, Semen Ginkgo and Radix Ginseng extract mix with any weight ratio, preferably mix with 2: 1: 1 weight ratios.
In order to be more suitable for taking of alzheimer disease, Cerebral Infarction Patients, can process granule or oral liquid with one or more pharmaceutic adjuvants in the active component in the above-mentioned Pharmaceutical composition.
Usefulness of the present invention; Having invented described Pharmaceutical composition can obviously improve superoxide dismutase in the mouse brain tissue (SOD) content and reduce malonaldehyde (MDA) content; Reduced the neural infringement of radical pair; Have avoiding and improve the new purposes of dementia, it is obvious simultaneously the dysmnesia animal to be improved memory effect, therefore has the memory of recovering dementia patients and the new purposes that improves student's learning memory aspect; Invented described Pharmaceutical composition to long-time use computer or dizziness that driving produced, head rise, the new purposes of headache and dim eyesight aspect.The invention allows for described Pharmaceutical composition and have the new purposes of hair growth promoting, anticreep originating party face.
In addition, described Pharmaceutical composition is processed granule or oral liquid, be fit to dementia and Cerebral Infarction Patients and take, thereby take to the patient again after need not tablet being pulverized.
The specific embodiment
The present invention combines embodiment to be further described.Below implementing the foster sheet of medium blue is the name of product of above-mentioned Pharmaceutical composition in " the homemade health food certificate of approval " of State Food and Drug Administration's approval, and authentication code is 2006B0578.
SOD and MDA measure in the embodiment 1 mouse brain tissue
Free radical acts on lipid generation peroxidization, and the oxidation end-product is malonaldehyde (MDA), can cause the cross-linked polymeric of life macromolecules such as protein, nucleic acid, and have cytotoxicity.Superoxide dismutase (SOD) is a kind of active substance that comes from life entity, can eliminate the harmful substance that organism produces in metabolic processes.
With chloral hydrate 350mg/kg intraperitoneal injection of anesthesia, sterilization, the neck median incision separates bilateral common carotid arteries with mice; Overlap No. 0 silk thread buckle subsequent use, tension screw thread, blocking blood flow 20min; Cutting off the about 0.3ml of blood-letting apart from tail point 1cm place simultaneously, heat is coagulated hemostasis, unclamps screw thread; Behind the perfusion 10min, blocking blood flow 20min once more.Observe 10min after the perfusion again the 2nd time, skin suture, the penicillin powder is spilt in the wound.Wherein sham operated rats is only separated common carotid artery, and threading is blocking blood flow not, not blood-letting of afterbody, and respectively organize identical with other observing time.The blue sheet of supporting is given in operation back, establish height, in low three dose groups, dosage is respectively 400mg/kg/d, 800mg/kg/d, 1200mg/kg/d, postoperative continues to raise and administration 15 days; The negative matched group of not administration group is irritated stomach equivalent redistilled water every day, the 15th day, puts to death; Get cerebral tissue, discard olfactory bulb and XIAONAO, about the cortex cerebral tissue 100mg of weighing left side, process 1% homogenate with the normal saline of pre-cooling; 3000r/min, centrifugal 10min gets supernatant; Assay method is according to SOD, MDA test kit description, and SOD unit representes cerebral tissue with NU/ml, and MDA unit representes with nmol/ml.Each group is measured the result referring to table 1.Average relatively adopts the t check between group.
Table 1 mouse brain tissue homogenate SOD and MDA content (
n=12)
*Be p＜0.01.
Cerebral tissue contains the abundant oxidized unsaturated fatty acid that is prone to; Be vulnerable to most the damage of free radical; Free radical causes destruction and the peroxidating and the MDA generation of unsaturated fatty acid on cell and the cell membrane, can tangible detrimental effect be arranged to learning and memory, and SOD can effectively remove multiple free radical; The infringement of MDA cellular function when alleviating hypoxic-ischemic, the active height of MDA content and SOD can be used to estimate the important indicator of brain tissue impairment and curative effect of medication in the cerebral tissue.From experimental result, the SOD activity obviously weakens (p＜0.01) in the negative control group mouse brain tissue, and MDA content then obviously increases (p＜0.01); And active obviously strengthen (p＜0.01) of SOD in each medication group mouse brain tissue; MDA content then significantly reduces (p＜0.01); Prompting is blue supports sheet and can obviously improve after the fourth ventricle in mice with vascular dementia cerebral ischemia vigor of perfusion back SOD again; Significantly reduce the MDA level simultaneously, alleviate the damage of radical pair brain, thereby play the effect that the protection cerebral tissue improves learning and memory function.
The result shows: SOD content in the fine raising fourth ventricle in mice with vascular dementia cerebral tissue of blue foster sheet ability, the while can be reduced the content of MDA, explains that the blue sheet of supporting has significant curative effect for improving fourth ventricle in mice with vascular dementia.
The influence of 2 pairs of dysmnesia mices of embodiment
Mice is carried out diving tower training, is fit to the diving tower environment, when mice when diving tower jumps off extremity contact copper grid, giving 24V voltage immediately stimulates, and mice is shocked by electricity 3 times, the normal avoidance response after mice is shocked by electricity is for escaping to platform.The record mice escape after being shocked by electricity to the time of platform be incubation period, and the electric shock number of times in the record 3min is an errors number.Stay one group to be normal group, the sodium nitrite of all the other mouse peritoneal injection 150mg/kg is made mouse memory obstacle model, and mouse memory obstacle model is divided into 3 groups; One group is model control group, irritates stomach and gives the normal saline with volume, and one group is the model positive drug control group; Irritate stomach and give piracetam, dosage is 0.5g/kg, and one group is the blue sheet group of supporting; Dosage is 1.2g/kg, carries out the test of DT-200 diving tower auto testing instrument, and the result is referring to table 2.
The blue foster sheet of table 2 causes the influence (
n=10) of mouse memory obstacle to sodium nitrite
Annotate: compare with model group,
*Be p＜0.05,
*Be p＜0.01;
Model group is short incubation period, and errors number is many, with the normal group significant difference, shows that dysmnesia appear in model group.Blue support sheet group and model group relatively, obviously prolong incubation period, the errors number minimizing, more approaching with the piracetam group.Research shows that blue foster sheet can improve the memory of dysmnesia mice.
Embodiment 3 promotes the hair growth test
Use 8% sodium sulfide to be depilatory, chaeta 1cm is sloughed at the back of 24 rat same positions
2, expose glabrous skin, be divided into three groups at random; One group of water of irritating stomach with volume, two groups give the blue sheet 800mg/kg/d of supporting, 1200mg/kg/d respectively in addition, and 10 new hair are taken off in each Mus depilation district at random after 25 days; Survey its length with micrometer at microscopically, average, the result is referring to table 3.
The blue influence (
n=8) of supporting sheet of table 3 to the rat hair growth
| Group | Dosage | New hair long (mm) |
| Matched group | 0 | 5.8±0.8 |
| The blue sheet low dose group of supporting | 600mg/kg/d | 8.4±1.1 * |
| The blue low high dose group of sheet of supporting | 1200mg/kg/d | 15.7±1.2 ** |
Annotate: compare with the blank group,
*Be p＜0.05,
*Be p＜0.01;
The result shows that blue two dose groups of sheet height of supporting are compared with the blank group, all can significantly promote the rat hair growth.
Embodiment 4 hypermnesis effects
Carried out 30 routine high school seniors and taken blue questionnaire survey of supporting sheet, hypomnesis, thinking are laxed to having before taking, the student of insomnia gives blue foster sheet 1 day 2 times, each 2, take for 1 week.The result sees table 4.
Table 4 high school student takes the blue sheet of supporting
The result shows that the blue sheet of supporting has tangible effect to student's improving memory.
Embodiment 5 hair-growing and anti-hair loss effects
Certain man, the doctor, 46 years old, alopecia 2 years was got a bit thin on top, took blue to support sheet 1 day 2 times, each 2, after 20 days, the crown begins to bear new hair color, after 45 days, return to alopecia basically before, explain that blue foster sheet has hair regrowth.
Certain woman, 3 years students of Shanghai university suffer from thyroid function and resist into, take hormone therapy 1 year.Hair comes off in a large number, and in the especially hair washing process, the hair that drops is obvious.Take blue foster sheet 1 day 2 times, each 2, after 1 week, in the hair washing process, the hair that drops obviously reduces, and after January, hair increases, and recovers normal.The blue effect that sheet has the control alopecia of supporting is described.
Embodiment 6 suffers from the senile dementia restitution
Zhao Yiran, the man, 84 years old, suffered from senile dementia 8 years, can't take care of oneself, can not talk, the speech irrationality is not familiar with the household.After taking blue foster sheet one and a half months (a day twice, once two), son goes out to remind the band raincoat; Greeting to the family relatives has answer, can tell sentence intermittently, to reading newspaper; See that TV responds, can express wish not for the thing of disliking, the mental status is good.The blue sheet of supporting has rehabilitative action to patients of senile dementia.
Embodiment 7 prevention senile dementia effects
Li Jinqin, woman, nineteen forty-six birth; Just suffer from hypertension, heart disease since four teens, the early retirement mastery of being in 2008 begins to occur forgeing, forgetful phenomenon; Said that the thing of telling was just turned round and forgotten, and often can not find thing or lose article; Sometimes kith and kin's name is not known yet, often talking nonsense.Through the Shanghai Xinhua hospital diagnosis is that senile dementia is early stage, takes the blue sheet of supporting after 20 days, forgets, forgetful phenomenon reduces, and can normally talk with the client, and health is also more and more healthy, has independently participated in old people's collective activity after two months.Meet others and always say that the blue sheet of supporting given her second spring.Explain that the blue sheet of supporting can prevent the generation of senile dementia.
Embodiment 8 granules
Support in the application process of sheet in indigo plant; The patients of senile dementia that the has blue sheet of supporting of swallowing is had any problem; Need be with accompanying in the meal after the foster sheet crushing of indigo plant or could obeying in the water down; Therefore the invention provides granule prescription and technology (referring to table 5), granule can add the water mixing to be swallowed, and makes things convenient for senile dementia, Cerebral Infarction Patients to take.Described prescription of present embodiment and technology is as the restriction to granule prescription, technology of the pharmaceutic adjuvant of above-mentioned Pharmaceutical composition and adding, has difference prescription that still available other the pharmaceutic adjuvant of pharmaceutics Professional knowledge person obtains or technology still in the scope that present embodiment provided.
Table 5 granule prescription and technology (being made into 100% at last)
With aminoacid, extract mixing, add starch and sucrose mix homogeneously in ratio in the table 5 again, add and process soft material, cross 14 mesh sieves and granulate, wet granular is in 50-60 ℃ of drying, and dried granule is crossed 14 mesh sieve granulate, and crosses 80 mesh sieves sieve and remove fine powder, promptly gets with the bag fill.
Embodiment 9 sugar-free granule
Adjuvant in Pharmaceutical composition and the table is processed sugar-free granule by technology, be fit to prohibit sugared old people and take.
Table 6 sugar-free granule is formed (being made into 100% at last)
In ratio in the table aminoacid, extract and adjuvant mix homogeneously are processed soft material with 95% ethanol, cross 14 mesh sieves and granulate, wet granular is in 50-60 ℃ of drying, and dried granule is crossed 14 mesh sieve granulate, and crosses 80 mesh sieves sieve and remove fine powder, promptly gets with the bag fill.
Embodiment 10 syrups
The characteristics of syrup are directly to take.
Table 7 syrup is formed (being made into 100% at last)
In ratio in the table 7 sucrose is joined in the distilled water that is heated to the about 800ml that boils, put after waiting to dissolve cold after, add aminoacid, extract mixing; Continue to add potassium sorbate, also can add the strong flavor of 50ml Pericarpium Citri junoris tincture and 5g citric acid and add, again adding distil water 1000ml; Stir, continue heating 15min, put cold; Packing, sterilization promptly gets.
Embodiment 11 oral liquids
The Sugarless type oral liquid is fit to prohibit sugared patient and takes.
Table 8 oral liquid is formed (being made into 100% at last)
In ratio in the table 8 aminoacid, extract are added the low amounts of water dissolving, add stevioside and saccharin sodium, adding distil water 1000ml, mixing is sterilized after the fill, promptly gets.
The rehabilitative action of 12 pairs of Cerebral Infarction Patients of embodiment
Fang Quanzhong, the man, 56 years old, high blood is arranged, do not take medicine.On the July 16th, 2010 of headache vomiting suddenly, the ether of losing consciousness, after diagnosing, left cerebral hemorrhage, hospital surgical treatment; On October 26th, 2010 left hospital, and left hand, left foot imperception began to take the made oral liquid by embodiment 8 on November 2nd, 2010; 1 day 2 times, each 20ml obtained report in November 28 in 2010; Mr. Fang Quanzhong can raise one's hand, and December 6 obtained report in 2010, and Mr. can stretch one's legs among the Fang Quan.Explain that Pharmaceutical composition of the present invention has rehabilitative action to Cerebral Infarction Patients.
13 couples of embodiment are long-time to use that dizzinesses, the head that computer produced rises, the effect of headache and dim eyesight aspect.
Having carried out 30 examples goes to work, uses computer to take the questionnaire survey of blue foster sheet as the staff of Work tool at office building.These staff's ages 28 are to 45 years old, male 14 people wherein, women 16 people, generally to afternoon be prone to that dizziness, head are risen, the phenomenon of headache and dim eyesight, the staff with these symptoms is given bluely to support sheet 1 day 2 times, each 2, took for 1 week.The result is referring to table 9.
Table 9 clerical workforce takes the blue sheet effect of supporting
Explain blue support that sheet can prevent and treat effectively that dizziness, the head that long-time use computer produced rises, headache and dim eyesight phenomenon.
14 pairs of dizzinesses that long-duration driving produced of embodiment, head rise, the effect of headache and dim eyesight aspect.
Carried out 60 routine taxi drivers's day shift and taken blue questionnaire survey of supporting sheet, the age 31 is to 45 years old, male 48 people wherein, women 2 people.Hangzhou is hired out driver general 6 to 7 day shifts of morning of driver and succeed daytime; About 5 of afternoons come off duty, generally reflect be prone to that dizziness, head are risen most at 2 to 5 in afternoon, the phenomenon of headache and dim eyesight, the driver with these symptoms is given bluely to support sheet 1 day 2 times; Each 2, took for 1 week.The result is referring to table 10.
Table 10 taximan takes the blue sheet effect of supporting
Explain blue support that sheet can prevent and treat effectively that the long-duration driving personnel occur that dizziness, head are risen, headache and dim eyesight phenomenon.
Claims (2)
1. the application of Pharmaceutical composition in preparation hypermnesis medicine formed of natural amino acid and natural extract; Said natural amino acid is ornithine and citrulline or its esters; Natural extract is Fructus Jujubae, Semen Ginkgo and Radix Ginseng extract, and wherein natural amino acid and natural extract mix with 4: 1 weight ratios; Ornithine and citrulline or its salt mix with 1: 1 weight ratio; Fructus Jujubae, Semen Ginkgo and Radix Ginseng extract mix with 2: 1: 1 weight ratios.
2. the application of Pharmaceutical composition according to claim 1 is characterized in that, said Pharmaceutical composition and pharmaceutic adjuvant are processed granule or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010616182A CN102058694B (en) | 2010-12-24 | 2010-12-24 | Application of pharmaceutical composition consisting of amino acids and extracts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010616182A CN102058694B (en) | 2010-12-24 | 2010-12-24 | Application of pharmaceutical composition consisting of amino acids and extracts |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100106280A Division CN102552457A (en) | 2010-12-24 | 2010-12-24 | Application of medicinal composition of amino acid and extracts |
| CN2012100106312A Division CN102526251A (en) | 2010-12-24 | 2010-12-24 | Application of composition of amino acids and extracts to preparation of drugs with function of preventing cerebral infarction |
| CN2012100106308A Division CN102526250A (en) | 2010-12-24 | 2010-12-24 | Application of composition of amino acids and extracts in preparation of drugs with function of improving memory |
| CN2012100106295A Division CN102600260A (en) | 2010-12-24 | 2010-12-24 | Medicinal use of composition of amino acids and extracts for preventing and treating senile dementia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102058694A CN102058694A (en) | 2011-05-18 |
| CN102058694B true CN102058694B (en) | 2012-09-05 |
Family
ID=43994319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010616182A Active CN102058694B (en) | 2010-12-24 | 2010-12-24 | Application of pharmaceutical composition consisting of amino acids and extracts |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102058694B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579620B (en) * | 2012-03-16 | 2016-03-23 | 浙江奥默生物医药有限公司 | A kind of compositions causes the medicinal usage of histologic lesion at control plasticiser |
| CN103054040B (en) * | 2013-01-13 | 2014-05-21 | 浙江奥默生物医药有限公司 | Pharmaceutical composition for increasing hypoxia tolerance |
| CN103040925A (en) * | 2013-01-13 | 2013-04-17 | 浙江奥默生物医药有限公司 | Medicinal composition with auxiliary protection effect to alcoholic liver injury |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100418548C (en) * | 2003-05-18 | 2008-09-17 | 漆又毛 | Medicinal composition and use thereof |
-
2010
- 2010-12-24 CN CN201010616182A patent/CN102058694B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100418548C (en) * | 2003-05-18 | 2008-09-17 | 漆又毛 | Medicinal composition and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102058694A (en) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5700457A (en) | Processed product for skin and hair treatment | |
| Tabor et al. | Corneal damage due to eye contact with chlorhexidine gluconate | |
| CN111888464A (en) | A health composition with antiaging and immunity enhancing effects | |
| Johnstone et al. | Endocrine system: part 1 | |
| CN102058694B (en) | Application of pharmaceutical composition consisting of amino acids and extracts | |
| CN109419800B (en) | Pharmaceutical composition and application thereof | |
| Zand et al. | Smart Medicine for Healthier Living: A Practical A-to-Z Reference to Natural and Conventional Treatments | |
| CN102526250A (en) | Application of composition of amino acids and extracts in preparation of drugs with function of improving memory | |
| CN102526251A (en) | Application of composition of amino acids and extracts to preparation of drugs with function of preventing cerebral infarction | |
| CN102552457A (en) | Application of medicinal composition of amino acid and extracts | |
| CN102600260A (en) | Medicinal use of composition of amino acids and extracts for preventing and treating senile dementia | |
| CN105982882A (en) | External-use medicine prepared from optically active material composition and used for treating haemorrhoids and preparation technology of external-use medicine | |
| World Health Organization | Malnutrition and disease: a major problem of the human race | |
| JP2000316528A (en) | Nutrition supplementing food for enhancing reproductive function | |
| CN103599190A (en) | Traditional Chinese medicine composition for treating light-headedness | |
| CN101897828A (en) | Pharmaceutical composition with chloasma-dispelling function and preparation method thereof | |
| Wilkes et al. | Consumers guide to cancer drugs | |
| Kumar et al. | A Case Report of Follicular Cyst: Case Report | |
| JPS5962526A (en) | Inorganic tonic medicine for improving human constitution | |
| Osborne | The principles of therapeutics | |
| Davis | On Gelsemium Sempervirens | |
| Schwartz | The hormone solution: Naturally alleviate symptoms of hormone imbalance from adolescence through menopause | |
| WO2022257693A1 (en) | Traditional chinese medicine composition for treating hypertension and preparation method therefor | |
| CN1156598A (en) | Medicine for treating thyreoidism | |
| Lindlahr et al. | The practice of nature cure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HANGZHOU AOMO MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: QI YOUMAO Effective date: 20140305 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140305 Address after: 7, No. 310011, 39 Cheung Road, Hangzhou, Zhejiang, Gongshu District Patentee after: Hangzhou Aomo Medical Technology Co., Ltd. Address before: 7, No. 310011, 39 Cheung Road, Hangzhou, Zhejiang, Gongshu District Patentee before: Qi Youmao |
|
| C56 | Change in the name or address of the patentee |
Owner name: HANGZHOU AOMO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HANGZHOU AOMO MEDICAL TECHNOLOGY CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 5, building 7, building 39, 310011 Cheung Road, Hangzhou, Zhejiang, Gongshu District Patentee after: HANGZHOU ADAMERCK PHARMLABS INC. Address before: 7, No. 310011, 39 Cheung Road, Hangzhou, Zhejiang, Gongshu District Patentee before: Hangzhou Aomo Medical Technology Co., Ltd. |